questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Benzopyranes
Coumarines
4-Hydroxycoumarines
4-Hydroxycoumarines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Language Development Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "4-Hydroxycoumarines : Questions médicales les plus fréquentes",
"headline": "4-Hydroxycoumarines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 4-Hydroxycoumarines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-10",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "4-Hydroxycoumarines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Coumarines",
"url": "https://questionsmedicales.fr/mesh/D003374",
"about": {
"@type": "MedicalCondition",
"name": "Coumarines",
"code": {
"@type": "MedicalCode",
"code": "D003374",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Acénocoumarol",
"alternateName": "Acenocoumarol",
"url": "https://questionsmedicales.fr/mesh/D000074",
"about": {
"@type": "MedicalCondition",
"name": "Acénocoumarol",
"code": {
"@type": "MedicalCode",
"code": "D000074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.079"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dicoumarol",
"alternateName": "Dicumarol",
"url": "https://questionsmedicales.fr/mesh/D001728",
"about": {
"@type": "MedicalCondition",
"name": "Dicoumarol",
"code": {
"@type": "MedicalCode",
"code": "D001728",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.203"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Biscoumacétate d'éthyle",
"alternateName": "Ethyl Biscoumacetate",
"url": "https://questionsmedicales.fr/mesh/D005017",
"about": {
"@type": "MedicalCondition",
"name": "Biscoumacétate d'éthyle",
"code": {
"@type": "MedicalCode",
"code": "D005017",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.451"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phenprocoumone",
"alternateName": "Phenprocoumon",
"url": "https://questionsmedicales.fr/mesh/D010644",
"about": {
"@type": "MedicalCondition",
"name": "Phenprocoumone",
"code": {
"@type": "MedicalCode",
"code": "D010644",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Warfarine",
"alternateName": "Warfarin",
"url": "https://questionsmedicales.fr/mesh/D014859",
"about": {
"@type": "MedicalCondition",
"name": "Warfarine",
"code": {
"@type": "MedicalCode",
"code": "D014859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.914"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "4-Hydroxycoumarines",
"alternateName": "4-Hydroxycoumarins",
"code": {
"@type": "MedicalCode",
"code": "D015110",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Li Sheng",
"url": "https://questionsmedicales.fr/author/Li%20Sheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Zahra Hosseini-Khah",
"url": "https://questionsmedicales.fr/author/Zahra%20Hosseini-Khah",
"affiliation": {
"@type": "Organization",
"name": "Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran."
}
},
{
"@type": "Person",
"name": "Saeed Emami",
"url": "https://questionsmedicales.fr/author/Saeed%20Emami",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. sdemami12@gmail.com."
}
},
{
"@type": "Person",
"name": "Jhonnathan Brawley",
"url": "https://questionsmedicales.fr/author/Jhonnathan%20Brawley",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States."
}
},
{
"@type": "Person",
"name": "Amarawan Intasiri",
"url": "https://questionsmedicales.fr/author/Amarawan%20Intasiri",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "PAX9 in Cancer Development.",
"datePublished": "2022-05-17",
"url": "https://questionsmedicales.fr/article/35628401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23105589"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of minimally invasive",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/35585965",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ymgmr.2022.100880"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functional impairment, insight, and comparison between criteria for gaming disorder in the International Classification of Diseases, 11 Edition and internet gaming disorder in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36326855",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/2006.2022.00079"
}
},
{
"@type": "ScholarlyArticle",
"name": "Harnessing a T1 Phage-Derived Spanin for Developing Phage-Based Antimicrobial Development.",
"datePublished": "2024-03-20",
"url": "https://questionsmedicales.fr/article/38516182",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.34133/bdr.0028"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development and validation of a youth climate anxiety scale for the Youth Development Instrument survey.",
"datePublished": "2023-08-21",
"url": "https://questionsmedicales.fr/article/37605318",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/inm.13201"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Benzopyranes",
"item": "https://questionsmedicales.fr/mesh/D001578"
},
{
"@type": "ListItem",
"position": 6,
"name": "Coumarines",
"item": "https://questionsmedicales.fr/mesh/D003374"
},
{
"@type": "ListItem",
"position": 7,
"name": "4-Hydroxycoumarines",
"item": "https://questionsmedicales.fr/mesh/D015110"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 4-Hydroxycoumarines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 4-Hydroxycoumarines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 4-Hydroxycoumarines",
"description": "Comment diagnostiquer une surdose de 4-hydroxycoumarines ?\nQuels tests sont utilisés pour surveiller le traitement par 4-hydroxycoumarines ?\nQuels symptômes indiquent une complication du traitement ?\nComment évaluer l'efficacité des 4-hydroxycoumarines ?\nQuels signes cliniques nécessitent une évaluation urgente ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development+Disorders&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 4-Hydroxycoumarines",
"description": "Quels sont les effets secondaires courants des 4-hydroxycoumarines ?\nComment reconnaître une réaction allergique aux 4-hydroxycoumarines ?\nQuels symptômes peuvent indiquer une thrombose malgré le traitement ?\nQuels signes indiquent une surdose de 4-hydroxycoumarines ?\nQuels symptômes nécessitent un ajustement de la dose ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development+Disorders&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 4-Hydroxycoumarines",
"description": "Comment prévenir les complications des 4-hydroxycoumarines ?\nQuelles précautions prendre lors de l'utilisation de 4-hydroxycoumarines ?\nComment éduquer les patients sur les 4-hydroxycoumarines ?\nQuels aliments éviter avec les 4-hydroxycoumarines ?\nComment gérer les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development+Disorders&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 4-Hydroxycoumarines",
"description": "Comment traiter une surdose de 4-hydroxycoumarines ?\nQuels médicaments interagissent avec les 4-hydroxycoumarines ?\nQuelle est l'alternative aux 4-hydroxycoumarines ?\nComment ajuster la dose de 4-hydroxycoumarines ?\nQuels sont les traitements de soutien lors d'une surdose ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development+Disorders&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 4-Hydroxycoumarines",
"description": "Quelles sont les complications possibles des 4-hydroxycoumarines ?\nComment gérer une hémorragie due aux 4-hydroxycoumarines ?\nQuels facteurs augmentent le risque de complications ?\nComment prévenir les thromboses sous traitement ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development+Disorders&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 4-Hydroxycoumarines",
"description": "Quels sont les facteurs de risque pour les complications des 4-hydroxycoumarines ?\nComment l'alimentation influence-t-elle l'efficacité des 4-hydroxycoumarines ?\nQuels médicaments augmentent le risque de saignement ?\nComment l'âge affecte-t-il le traitement par 4-hydroxycoumarines ?\nQuels antécédents médicaux sont préoccupants ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development+Disorders&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une surdose de 4-hydroxycoumarines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests de coagulation et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour surveiller le traitement par 4-hydroxycoumarines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le temps de prothrombine (TP) et l'INR sont les tests principaux pour surveiller l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une complication du traitement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels, des ecchymoses ou des douleurs abdominales peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des 4-hydroxycoumarines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des événements thromboemboliques et les résultats des tests de coagulation."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques nécessitent une évaluation urgente ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de saignement grave, comme des hémorragies cérébrales ou gastro-intestinales, nécessitent une évaluation urgente."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des 4-hydroxycoumarines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des saignements, des nausées et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux 4-hydroxycoumarines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une réaction allergique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une thrombose malgré le traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs, un gonflement ou une rougeur dans une jambe peuvent indiquer une thrombose persistante."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose de 4-hydroxycoumarines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements excessifs, des ecchymoses et des douleurs abdominales peuvent indiquer une surdose."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un ajustement de la dose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements fréquents ou des résultats d'INR élevés peuvent nécessiter un ajustement de la dose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications des 4-hydroxycoumarines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière de l'INR et une éducation des patients sont essentielles pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de l'utilisation de 4-hydroxycoumarines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les activités à risque de blessure et informer les professionnels de santé de l'utilisation."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les 4-hydroxycoumarines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer sur les effets secondaires, l'importance des tests de coagulation et les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quels aliments éviter avec les 4-hydroxycoumarines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments riches en vitamine K, comme les légumes à feuilles vertes, pour maintenir l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment gérer les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consulter un professionnel de santé avant de prendre d'autres médicaments pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Comment traiter une surdose de 4-hydroxycoumarines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'administration de vitamine K et la surveillance des paramètres de coagulation."
}
},
{
"@type": "Question",
"name": "Quels médicaments interagissent avec les 4-hydroxycoumarines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques, des anti-inflammatoires et certains antifongiques peuvent interagir avec ces anticoagulants."
}
},
{
"@type": "Question",
"name": "Quelle est l'alternative aux 4-hydroxycoumarines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants directs comme le rivaroxaban ou l'apixaban sont des alternatives possibles."
}
},
{
"@type": "Question",
"name": "Comment ajuster la dose de 4-hydroxycoumarines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose est ajustée en fonction des résultats de l'INR et des facteurs de risque individuels."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements de soutien lors d'une surdose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions de plaquettes et des soins intensifs peuvent être nécessaires en cas de surdose sévère."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des 4-hydroxycoumarines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des hémorragies, des thromboses et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment gérer une hémorragie due aux 4-hydroxycoumarines ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt du médicament, l'administration de vitamine K et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies hépatiques et l'utilisation concomitante d'autres anticoagulants augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment prévenir les thromboses sous traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un suivi régulier et ajuster la dose en fonction des résultats de l'INR pour prévenir les thromboses."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des difficultés respiratoires ou des saignements importants indiquent une complication grave."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les complications des 4-hydroxycoumarines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de thrombose, l'âge avancé et les maladies hépatiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle l'efficacité des 4-hydroxycoumarines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en vitamine K peut réduire l'efficacité des 4-hydroxycoumarines."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque de saignement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires non stéroïdiens (AINS) et certains antibiotiques peuvent augmenter le risque de saignement."
}
},
{
"@type": "Question",
"name": "Comment l'âge affecte-t-il le traitement par 4-hydroxycoumarines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir une sensibilité accrue et nécessiter un ajustement de la dose."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont préoccupants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies hépatiques ou de troubles de la coagulation sont préoccupants lors du traitement."
}
}
]
}
]
}
Paired box 9 (PAX9) is a transcription factor of the PAX family functioning as both a transcriptional activator and repressor. Its functional roles in the embryonic development of various tissues and ...
Glycogen storage disease type Ia (GSD Ia) is an autosomal recessive disorder caused by deficiency of glucose-6-phosphatase (G6Pase), resulting in fasting hypoglycemia. Dietary treatment with provision...
Our objectives were: 1) establishing the use of a minimally invasive...
This study evaluated the consistency between the International Classification of Diseases, 11th Edition (ICD-11) for gaming disorder (ICD-11-GD) and Diagnostic and Statistical Manual of Mental Disorde...
We recruited 60 participants with GD, 45 participants who engaged in hazardous gaming (HG), and 120 controls based on a diagnostic interview. Their operationalization of functional impairment and stag...
We observed satisfactory consistency (kappa value = 0.80) with a diagnostic accuracy of 91.5% between the ICD-11-GD and DSM-5-IGD criteria. Furthermore, 16 participants with IGD in DSM-5 were determin...
There is a good consistency between ICD-11-GD and DSM-5-IGD criteria. The ICD-11 criteria have a high threshold for diagnosing GD. HG criteria could compensate for this high threshold and identify ind...
The global increase in the prevalence of drug-resistant bacteria has necessitated the development of alternative treatments that do not rely on conventional antimicrobial agents. Using bacteriophage-d...
Emerging terms in the literature such as climate anxiety describe heightened concern, fear, and anxiety related to the climate crisis. Recent efforts have attempted to develop and validate scales to m...
While evaluation of research-to-policy projects is a fundamental aspect of measuring the impact of new knowledge, limited studies have examined evaluation methods in such projects, as well as how the ...
In light of the expanding role of pharmacy in addressing global health challenges of Universal Health Coverage, advancing pharmacy practice to provide more effective pharmaceutical services has become...
A mixed methods approach was used to conduct a series of exploration, development, and consensus phases. The exploratory stage included desk research focused on innovative pharmaceutical provision glo...
The exploratory stage produced a draft set of 13 unvalidated FIP Practice Development Goals (DGs) Framework (v0). Initial analysis of the mNGT showed complex intersections between the proposed set of ...
A systematic goals-oriented development framework was developed to respond to pharmaceutical development needs and support a needs-based roadmap for a sustainable pharmacy practice transformation glob...
Pharmacy education shifts toward competency-based training to meet healthcare demands. This study aims to develop and validate the Kuwait Advanced Competency Framework (KACF) for pharmacists. The stud...
This is a mixed methods study that employed an "adopt and adapt" approach. The KACF was adopted from the FIP GADF and adapted following four phases. Phase one involved checking and validating the Arab...
The translation phase verified a bilingual framework that could be utilized by pharmacists in Kuwait. The initial and final validation phases identified 20 behavioral statements (out of 22 in the orig...
The KACF emerges as a pivotal tool for advancing pharmacy services in Kuwait, aligning with global trends toward competency-based education. Findings underscored the necessity for context-specific app...
The Accreditation Council for Pharmacy Education (ACPE) defines continuing professional development (CPD) as a self-directed, ongoing, systematic, and outcomes-focused approach to lifelong learning th...
This was an exploratory study using cross-sectional surveys and pharmacist self-reported CPD data at a community health system in the Southeastern USA. Surveys evaluating perceived value and use of CP...
Overall, fifty-seven (33.1%) pharmacists and twelve (85.7%) pharmacy managers and directors responded to surveys. A total of 13 (22.8%) respondents strongly agreed and 21 (36.8%) respondents agreed th...
The CPD framework may be a useful approach to support pharmacist development in hospital and health system settings and facilitate performance reviews....
Mood swings, or mood variability, are associated with negative mental health outcomes. Since adolescence is a time when mood disorder onset peaks, mood variability during this time is of significant i...